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Activation of the inflammatory response of neutrophils by Tamm-
Horsfall glycoprotein. The activation of human polymorphonuclear
leukocytes (PMN) by particulate Tamm-Horsfall glycoprotein (THG)
represents an interaction hitherto unrecognized, The potential patho-
physiological effect of this phenomenon within the interstitium of the
kidney is highlighted by the activation of the respiratory burst, as well
as by comprehensive PMN degranulation. Products of the interaction
are expressed in terms of phagocytosis, luminol-dependent chemilumi-
nescence, granule marker enzyme release and arachidonic acid metab-
olism. Significant quantities of the primary, secondary and tertiary
granule markers, myeloperoxidase, vitamin B12 binding protein and
N-acetyl-f3-D-glucosaminidase, respectively, were secreted in a dose
and time-dependent manner. Phagocytosis of the glycoprotein was
accompanied by the generation of significant quantities of leukotriene
B4. Furthermore, the ability of such a particulate ligand to activate the
alternative pathway of complement clearly represents a capacity to
augment the inflammatory response. Should the interaction of THG
with PMN take place within the interstitium of the kidney, augmented
by the deposition of complement proteins on the surface of insoluble
aggregates, the resulting inflammatory response may lead to marked
tissue damage and eventually result in interstitial fibrosis.
Tamm-Horsfall glycoprotein (THG), synthesized exclusively
by the kidney [1], is normally found in both serum [2, 3] and
urine [4, 5]. Up to 100 mg/day is excreted in human urine by
healthy subjects [6, 7] in the form of large aggregates, with an
apparent molecular weight in excess of 7 x 106 kD [81.
Immuno-ultrastructural studies have demonstrated that THG is
located to the epithelial cells of the thick ascending limb of the
loop of Henle and the distal convoluted tubule [9—11]. A
physiological role for THG has yet to be established, however,
it has been suggested that this glycoprotein may be involved in
sodium and water homeostasis and that it participates in the
generation of the hypotonic fluid delivered to the distal neph-
ron, probably by rendering the thick ascending limb of the loop
of Henle impermeable to water [12, 131.
In contrast, a number of studies have suggested a patholog-
ical role for THG. The capacity of THG to bind certain bacterial
cell components may modify the host response and allow for
persistence of infection [14]. In addition extratubular deposits
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of THG, particularly in interstitial regions, have been demon-
strated in immunopathological studies of several other human
tubulointerstitial diseases [15—17]. Histological examination of
animal models of interstitial nephritis have identified an asso-
ciation between THG deposition and renal parenchymal inflam-
mation. Scarring occurred when the kidney was challenged with
sterile urine, but not when challenged with THG-depleted
homologous urine [18, 19]. In such models, interstitial deposits
of THG, IgG and C3 co-exist with a heavy leukocyte infiltrate
[15, 16, 19, 20]. While the predominant cell type has been
reported as lymphocyte and/or macrophages/mononuclear
cells, the early infiltration of neutrophils (PMN) has also been
highlighted [20]. Furthermore, in other models of interstial
inflammation an early infiltrate of PMN is recognized [21].
These cells are soon replaced by mononuclear cells and lym-
phocytes during the progression of the response. As a result of
these observations, it has been suggested that the interstitial
inflammation produced in the above animal models is a direct
result of the inflammatory response directed against THG [18].
The present study examines the interaction between particu-
late THG and PMN and demonstrates a significant capacity for
the particulate form of this glycoprotein to activate the respira-
tory burst, to trigger comprehensive PMN degranulation and to
generate significant quantities of leukotriene (LTB4). The re-
sults indicate a significant capacity for this glycoprotein to
stimulate PMN in vitro and illustrates a potential pro-inflam-
matory role for particulate THG when present in the renal
parenchyma.
Methods
Preparation of human neutrophils
Normal human blood leukocytes were isolated from citrated
blood by dextran sedimentation of erythrocytes, rendered
plasma free and platelet poor by washing three times in phos-
phate buffered saline, pH 7.4 (PBS), and purified by density-
gradient centrifugation on cushions of Ficoll-Hypaque (Phar-
macia, Uppsala, Sweden). The PMN were counted on a Coulter
counter (Coulter Electronics, Luton, UK) after contaminating
erythrocytes were removed by hypotonic lysis with cold 0.2%
(wt/vol) NaCI. The final preparation was stored in PBS at 4°C
until required. Preparations were judged to be 98% pure on the
basis of their morphology after examination of Wright-stained
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[221 centrifuged preparations (Cytospin II, Shandon Southern
Products, Runcorn, UK).
Agonists
Zymosan A (500 mg; Sigma Chemical Co., Poole, Dorset,
UK) was boiled for 20 minutes and washed three times in 50 ml
of 0.9% (wt/vol) NaCI, counted, and resuspended to a final
concentration of 10 mg/mI (5 x 108 particles per ml). Rabbit
erythrocytes were washed and stored at 4°C in Veronal-
buffered saline, pH 7.5, containing 0.1% (wt/vol) gelatin.
Laminin was extracted and purified from the Engelbreth-
Holm-Swarm sarcoma [23]. Aggregated laminin was formed on
storage at —20°C [23]. Chromatographically-pure porcine stom-
ach glycoprotein was obtained from Dr. P. Kearney, Welsh
School of Pharmacy, University of Wales College of Cardiff.
The calcium ionophore A23 187 (Cambridge Bioscience, Cam-
bridge, UK) and cytochalasin B (Sigma) were stored in aliquots
at 10 m concentrations in dimethyl sulfoxide at —70°C.
Tamm-Horsfall glycoprotein (THG)
THG was prepared from pooled normal human urine by
repeated NaC1 precipitation [24]. The washed (X 5) and dia-
lyzed precipitate was lyophilized, and particulate THG was
re-suspended in the appropriate buffer at 1 mg/ml (2 X io
particles/ml). Soluble THG was prepared by solubilizing partic-
ulate THG (10 mg) in 5 ml of 8 M urea and passing the solution
over Sepharose 4B 3 x 150 cm) equilibrated in 0.03 M sodium
phosphate, pH 6.8, containing 2 M urea. Soluble THG eluted as
a single peak. The purity of the final preparation was assessed
on SDS-polyacrylamide gel electrophoresis (SDS/PAGE) [25].
The gels were stained with Coomassie blue R-250, silver nitrate
or Schiff's reagent or transferred to Nitrocellulose and detected
by Western blots. Alternatively the THG was labelled with
Na 125J (Amersham International, Cardiff, UK) by the chloram-
me T method and gels subjected to autoradiography [7]. Endo-
toxin content of human THG was determined by the limulus
lysate assay [26].
Alternative complement pathway activation
The capacity of THG to activate the alternative complement
pathway (ACP) was assessed according to the method of Riches
and Stanworth [27] and compared to the activity of unopsonized
zymosan [28]. Briefly, the total available alternative pathway
haemolytic complement was estimated using rabbit erythro-
cytes and a range of dilutions of human serum chelated with
10.0 mM ethylene-glycol-bis-aminotetraacetate (EGTA) and 7
mM MgCI2. Initial experiments established the dilution of serum
that lysed 50% of a known concentration of these erythrocytes
(CH50). The capacity of the test ligands to deplete this diluted
serum of its complement activating capacity was established
over a range of ligand concentrations.
Assay of phagocytosis
PMN were washed and resuspended in RPM! 1640 (Gibco
Ltd., Paisley, Scotland, UK) containing 0.2% (wt/vol) bovine
serum albumin (Sigma) and 5 mr's MgCl2 (RPMI-Mg) to a
concentration of 5 x 106 cells/mi. One milliliter of PMN
suspension was added to 35 mm tissue culture plates and
incubated at 37°C in 5% CO2 for 20 minutes, and then washed
three times with RPMI-Mg (2 ml). The number of adherent cells
were calculated following estimations by Coulter counter of
non-adherent cells. The PMN monolayers were incubated for
one hour with various concentrations of particulate TUG sus-
pended in RPM!-Mg. The monolayers were then washed three
times with PBS, air dried, fixed and stained with Wright's stain.
The percentage of cells ingesting two or more particles were
estimated by light microscopy [27, 28]. Phagocytosis was con-
firmed by staining monolayers with trypan blue followed by
estimation with phase-contrast microscopy [27—29]. At least 200
PMN/plate were examined.
To test the effect of cytochalasin B on phagocytosis the stock
solution was diluted to the desired concentration in RPMI-Mg
and incubated in 1 ml volumes with PMN monolayers for five
minutes at 37°C. The supernatant was then decanted, and 1 ml
of RPMI-Mg containing TUG particles was added. Phagocyto-
sis was determined after incubation for one hour as above.
Control incubations consisted of monolayers pretreated for five
minutes at 37°C with RPM!-Mg alone prior to incubation with
particulate THG.
Method for chemiluminescence (CL) assays
CL was measured using a Berthold LB 950-T automatic
luminescence analyzer at 37°C. Samples for CL assays con-
tained 200 d Kreb's Ringer phosphate buffer, pH 7.4, contain-
ing 0.54 mr's Ca2, 1.2 mM Mg2 and 11.0 mr's D-glucose
(KRPG), 100 pi PMN (5 x 106/ml) and 100 1d of 10 pM luminol
(5-amino 2,3 dihydro 1,4 thalazinedione). All samples were
preincubated at 37°C for six minutes before the addition of THG
in order to achieve temperature equilibration and record back-
ground CL. The target particles in a volume of 100 pi KRPG
were added to the cuvettes and each reaction mixture was
assayed for CL sequentially over 120 minutes.
In separate experiments the particulate THG was replaced
with 100 d of a solution of calcium ionophore A23 187 in KRPG
and the CL determined as above.
Opsonization of particulate THG
Twenty milligrams of TUG were suspended in 1 ml of KRPG.
Three milliliters of fresh human serum was added, mixed
thoroughly, and incubated for 30 minutes at 37°C, washed by
centrifugation (x5) and resuspended to 4 ml in KRPG. Serum
treated THG was stored at —20°C. Opsonization was also
carried out in the presence of 10 mM EDTA; in the presence of
10 mM EGTA containing 10 mrs MgCI2 or with serum previ-
ously heat inactivated for one hour at 56°C.
Enzyme secretion
One hundred microliters of KRPG containing 5 x iO PMN
was diluted with 300 s1 of KRPG at 37°C before the addition of
particulate THG suspended at various concentrations in 100 l
of KRPG. The mixture was incubated at 37°C for periods up to
four hours. At the end of the incubation period the suspension
was centrifuged at 11000 x g for one minute and the supernatant
removed for enzyme assays. Controls, which were performed
for each experiment, consisted of supernatant obtained from
unstimulated cells incubated in KRPG for periods up to four
hours without particulate THG. The percent release of enzymes
from the PMN were calculated, after subtraction of the appro-
priate blank values, as a percentage of that released from cells
disrupted by sonication for two one-minute periods at 8 pm
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peak-to-peak distance at 4°C in a 150 W ultrasonic disintegrator
(MSE, Crawley, UK).
In a separate series of experiments cytochalasin B was
diluted to the desired concentration in KRPG. To 300 d of this
solution was added 100 .ul of KRPG containing 5 x l0 PMN
and the suspension incubated for five minutes at 37°C prior to
the addition of particulate THG. Enzyme release in cytochala-
sin B treated PMN in response to particulate THU in all cases
was compared with control cells preincubated for five minutes
in KRPG alone.
Myeloperoxidase
One hundred microliters of supernatant were incubated at
30°C with 1 ml of substrate consisting of 0.3 mii 0-dianisidine,
0.03% (vol/vol) H2O2, and 0.5% (vol/vol) Triton X-100 in 0.1 M
citric acid, pH 5.5 [301. The reaction was stopped after five
minutes with 1 ml of 3.25 M perchioric acid and the absorption
at A560 measured in Cecil CE 292 spectrophotometer (Cecil
Instruments Ltd., Cambridge, UK).
Vitamin B12 binding protein
One hundred microliters of supernatant and 250 d of [57Co]-
cyanocobalamin (4.44 ng/ml in water, 0.067 sCi/ml) were incu-
bated at room temperature for 30 minutes [31]. Activated
charcoal (Norit GSX; 5% wt/vol) coated with 1% (wt/vol)
bovine serum albumin was added and left at room temperature
for 10 minutes before centrifugation at 2500 x g to separate
charcoal-absorbed, non-protein bound vitamin ,. The super-
natant (1 ml) was counted for one minute in a gamma counter
(Kontron Instruments, St. Albans, UK).
N-acetyl-/3-D-glucosaminidase
One hundred microliters of supernatant were incubated with
100 d of substrate buffer (0.2 mM 4-methylumbelliferyl-N-
acetyl-/3-D-glucosamine in 0.1 M sodium citrate-phosphate
buffer, pH 4.3) were incubated for 16 hours at 37°C. The
reaction was terminated by the addition of 2 ml of 0.05 M
glycine buffer, pH 10.4, containing 5 mrvi EDTA. The 4
methylumbelliferone released was measured with an excitation
wavelength of 365 nm and an emission wavelength of 450 nm in
an Aminco Bowman spectrophotofluorimeter (American Instru-
ment Co. Inc., Silver Spring, Maryland, USA).
Lactate dehydrogenase
To 300 d of supernatant was added 200 tl of 10 mM f3-NADH
in water and 2.4 ml of 0.1 M potassium phosphate buffer, pH 7.4
[33]. The reaction was started by the addition of 100 d
potassium pyruvate (1 mg/ml), and the decrease in extinction at
340 nm was measured over four minutes in a Cecil CE 292
spectrophotometer fitted with a reaction rate calculator.
Generation of leukotrienes by particulate THG
PMN monolayers were washed three times with Tyrodes
solution containing 1 mM Ca2, 5 mt Mg2 and 0.1% (wt/vol)
gelatin (TG). THU was washed in TG and resuspended to the
required concentration. One milliliter of this suspension was
then added to each petri dish and incubated at 37°C in 5% CO2.
After the required incubation period, the supernatants were
removed and centrifuged at 11000 x g for 30 seconds to remove
debris and were stored at —70°C. The cell monolayer was
extracted overnight at —20°C with 1 ml of 100% methanol. The
cell extracts were evaporated to dryness (Univap centrifugal
evaporator, Univap, London, UK) and resuspended in 1 ml of
0.1 M Tris-HCI buffer, pH 7.4, containing 0.1% (wt/vol) gelatin
and 0.15 M NaCI (leukotriene assay buffer).
The radioimmunoassay for LTB4 [34] in the PMN superna-
tants and in resuspended PMN extracts was performed in a final
volume of 300 d that contained equal volumes of sample or
synthetic LTB4 from Dr. B. Spur), [3H]-LTB4 (211 Cifmmol;
Amersham International, Cardiff, UK) and immune rabbit
plasma to LTB4 coupled to bovine serum albumin [35]. The
reaction mixtures were incubated at 37°C overnight before
separation of the bound and the free tracer by addition of 1%
(wt/vol) dextran-coated charcoal (200 pi), and centrifugation at
3000 x g for 10 minutes at 4°C. The supernatants were counted
for radioactivity in an LKB Rackbeta scintillation counter. The
standard curve for the inhibition of binding of [3H]-LTB4 to
antibody was linear over the range 0.1 to 4.0 ng for synthetic
LTB4.
Trypsin treatment of PMN
Suspensions of PMN at 1 x 107/ml were incubated with
trypsin (specific activity 3.38 x 10 moLlmin/mg, using benzoyl-
DL-arginine-p-nitroanilide HCI as a substrate, pH 7.5, 40°C;
Sigma) at concentrations ranging from 100 ng to 10 g/ml in
PBS at 37°C. After 10 minutes the PMN were washed (x3) in
PBS containing soya bean trypsin inhibition (100 g/ml), once
with PBS alone, and finally resuspended in KRPG. The final
suspension was recounted in a Coulter counter and adjusted
with KRPG to a concentration of 5 x 106/ml.
Proteolytic digestion of THG
THU (90.5 mg) was resuspended in 7.5 ml of 50 mM sodium
borate, pH 8.5, containing 15 mrvi CaCl2 and 2.7 mg of pronase
[36]. The suspension was incubated at 37°C for 24 hours after
which time the digest was lyophilized. The resulting products
were dissolved in 0.1 M acetic acid (2 ml) and applied to a
column (1.7 cm x 90 cm) of Sephadex U-SO previously equili-
brated in 0.1 M acetic acid. The material was eluted with the
same buffer and fractions (1 ml) assayed for protein [37], neutral
sugars [38] and N-acetyl neuraminic acid [39]. The glycopep-
tides, which eluted in the void volume, were lyophilized,
redissolved in 0.1 M acetic acid (2 ml) and chromatographed on
a column (1.7 cm x 90 cm) of Sephadex G-lOO equilibrated in
the same buffer. Fractions were again assayed as above. The
fractions containing the glycopeptides were bulked (Fig. 11),
lyophilized, and finally desalted on Sephadex U-So equilibrated
in water. The two preparations (detailed in Fig. 11) were
freeze-dried and subjected to gas chromatographic analysis
[40]. Finally, the preparations were dissolved in KRPU (1
mg/mi) and stored at 4°C.
Results
Characterization of THG
Several batches of particulate THG were prepared from
separate collections of pooled human urine. The results ex-
pressed through this study relate to at least four separate
preparations of THU. After electrophoresis in the presence of
SDS and under non-reducing conditions and visualization with
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Fig. 1. Characterization of THG. Samples were resolved on SDS/PAGE
(10% acrylamide) and identified by: A. Lane 2, staining with Coomassie
Brilliant Blue, Lane 3, autoradiography. B. Lane 2, staining with Coomassie
Brilliant Blue, Lane 3, immunoblotting with rabbit anti-human THG antibody.
Positions of molecular mass markers are indicated in (A) Lane 1 and (B)
Lane I.
Coomassie blue R-250 (Fig. 1(a) lane 2 and 1(b) lane 2), silver
nitrate or Schiff's reagent (data not shown) the THG ran as a
single band of 90-95 kD. Figure 1(a) lane 3 and 1(b) lane 3,
respectively, are the autoradiographic and Western blots of
SDS/polyacrylamide gels of purified THG. Both show a single
band at 90-95 kD. Each preparation was judged endotoxin-free
(<2.5 pg/mi) as determined by the limulus lysate assay.
Activation of the alternative complement pathway by THG
Particulate human THU incubated over a range of concentra-
tions (62 to 2000 sg/mi) with chelated normal human serum
demonstrated a significant dose-dependent ability to activate
complement via the alternative pathway (Fig. 2). THG achieved
50% consumption at a concentration of 900 p.g/ml, In compar-
ison the concentration of zymosan particles to give a similar
consumption was 100 tg/ml. In contrast to the particulate
preparations soluble (monomer) THG (500 tg/ml) did not
activate the alternative pathway.
PMN phagocytosis in response to particulate stimuli
THG particles were phagocytosed by human PMN in a dose
dependent manner and in the complete absence of serum
opsonins (Fig. 3). At a concentration of 2 x l0 particle s/mI (1
mg/mi) a mean (N = 3) of 41 10% of adherent neutrophils had
ingested two or more particles of THU when incubated for 60
minutes at 37°C. At this particle concentration the ingestion of
THG was time dependent, reaching a plateau by 30 minutes
(Fig. 4). In the monolayers preincubated with cytochalasin B (5
.g/ml) and challenged with particulate THG (1 mg/mi) there
was a mean 33% reduction in phagocytosis.
Lumino/-dependent chemiluminescence
Human PMN generate CL when stimulated with unopsonized
THG in a dose dependent manner. At a concentration of 2 x iO
particles/mi, a mean (N = 3) of 2.1 0.6 x iO integrated cpm
were emitted. In the presence of opsonins however, there was
a mean twofold rise in generated CL to a peak of 4.1 x io cpm
(Fig. 5).
The generation of CL by PMN stimulated with particulate
THG (2 x IO particles/mI) was time-dependent, reaching a
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Fig. 2. Dose-dependent activation of human alternative complement
pathway by (•) unopsonized particulate THG and (V) unopsonized
zymosan. Results are expressed as the percentage of consumed com-
plement in Mg EGTA-chelated human serum. The data represents the
mean SD of 3 separate experiments with serum from 3 donors.
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Fig. 3. Dose-dependent phagocytosis of particulate THG by human
PMN monolayers. Unopsonized particulate THG (0.125 to 2.0 )< io
particles/mi) incubated with PMN monolayers for 60 mm. The results
are the mean SD of 3 experiments with cells from 3 separate donors.
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Fig. 5. Dose effect of (•) unopsonized and (ix) opsonized THU parti-
cles on the capacity of 5 X io human PMN to generate luminol-
dependent CL over 120 mm incubation period. The data represents the
mean of 3 separate experiments with cells from 3 different donors. The
CL is expressed as the integrated cpm (10—6) for the total incubation
period.
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Fig. 6. The time course of luminol-dependent CL response of 5 X io
PMN to: (i) unopsonized particulate THG (•); (ii) particulate THG
pretreated with normal human serum (A); (iii) particulate THG pre-
treated with human serum chelated with 10 mM EGTA containing 10 mM
MgC!2 (•); (Iv) particulate THG pretreated with human serum chelated
with 10 m EDTA (A); (v) particulate THG pretreated with heat
inactivated human serum at 56°C for 60 mm (0). The final concentra-
tion of particulate THG was 2 x iO particles/mi for each experiment.
The data represents the mean of 3 separate experiments using cells from
different donors.
PMN degranulation in response to stimulation by THG
Stimulation of human PMN (5 x l0) by particulate THG,
resulted in the release of the granule markers in a dose
10 20 30 40 50 60
10 20 30 40 50 60 70 80 90 100 110 120
Time, minutes
Fig. 4. Time-dependent phagocytosis of particulate THG by human
PMN monolayers. Unopsonized particulate THG (2)< iO particles/mi)
incubated with PMN monlayers over the time period 0 to 60 mm. The
results are the mean of 3 experiments with cells from 3 separate
donors.
peak value of 3.5 x j5 cpm after 40 minutes of incubation (Fig.
6). Opsonization of particulate THG with normal human serum
resulted in a fourfold increase in CL. Chelation of human serum
with 10 mtt Mg-EGTA resulted in a 40% reduction in peak CL.
Chelation of serum with 10 mrsi EDTA or heat inactivation of
serum at 56°C for one hour abolished the opsonic enhancement.
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Fig. 8. Dose effect of unopsonized THG particles on the capacity of
human PMN monolayers to release immunoreactive LTB4 after 30 mm
of incubation. The results are expressed as the mean SD of separate
experiments with cells from 3 different donors.
cytochalasin B pre-treatment resulted in the release of 15 3%;
N = 3 myeioperoxidase, 44 1.8% vitamin B12 binding protein
and 20.8 1.3%; N = 3 N-acetylglucosaminidase.
Generation of leukotrienes from PMN stimulated with
particulate THG
Monolayers of human PMN incubated at 37°C for 30 minutes
released immunoreactive LTB4 in response to THG in a dose-
dependent manner (Fig. 8). The generation of LTB4 was also
time-dependent, reaching a plateau after 30 minute incubation
(Fig. 9). At a concentration of 2 x i07 particles/mi there was a
mean release of 2.5 0.4 ng immunoreactive LTB4/106 PMN.
The distribution of the product was predominantly extracellular
but approximately 30% was retained within the cells (Fig. 9).
Effect of trypsin on the CL response of PMN to THG
The preincubation of PMN with increasing concentrations of
trypsin resulted in a dose-dependent decrease in the PMN CL
response from a maximum emission of 3.1 x l0 cpm in the
absence of protease treatment to a low of 1.2 x iø cpm at a
trypsin concentration of 10 p.g/ml (Fig. 10). LDH release was
<2% at the highest concentration of trypsin used. In contrast
trypsin pretreatment did not decrease the generation of CL by
PMN in response to calcium ionophore A23 187. Control PMN
stimulated with 2 /LM A23 187 resulted in a mean emission (±sD)
of 12.1 5.3 x i0 cpm/5 x i0 cells. Preincubation of PMN
with trypsin at a concentration of 1 g/ml prior to stimulation
Particle concentration/mi, x io
Fig. 7. Dose-dependent effect of unopsonized particulate THG on the
capacity of 5 X jo human PMN to release granule marker enzymes
over a 4 hour incubation period. (A) Myeloperoxidase (MPO) (primary
granule); (B) vitamin B1., binding protein (Vit B12 protein) (secondary
granule); (C) N-acetyi-/3-D-glucosaminidase (NAGase) (tertiary gran-
ule). Data are expressed as the means SD for 3 separate experiments
using cells from 3 different donors.
dependent manner (Fig. 7). PMN in suspension when stimu-
lated for four hours at 37°C with 1 mg/mI THG (2 X l0
particles/mI) released 31 5%; N = 3 myeloperoxidase (pri-
mary granule), 48 9%; N = 3 vitamin B12 binding protein
(secondary granule) and 34 20%; N = 3 N-acetyl-/3-D-
glucosaminidase (tertiary granule), respectively. Lactic dehy-
drogenase release was less than 2% of the total, indicating that
the above enzyme release was due to secretion and not cell
lysis. Furthermore, particulate THG (2 x iQ particles/mi)
induced the release of myeloperoxidase, vitamin 12 binding
protein and N-acetylglucosaminidase from PMN in a time-
dependent manner (data not shown).
In a separate series of experiments the preincubation of PMN
with cytochalasin B (5 p.g/ml) did not influence the release of
marker enzymes. Under conditions where there was a mean
33% decrease in the phagocytosis of particulate THG there was
a release of 15 4%; N = 3 myeloperoxidase, 42.8 2.4%; N
= 3 vitamin B12 binding protein and 19.6 2.2%; N = 3
N-acetylglucosaminidase. Control incubations in the absence of
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10 20 30 40 50 60
Time, minutes
Fig. 9. Time course of generation of intracellular (0) and extracellular
(•) immunoreactive LTB4 by PMN monolayers stimulated by 2 x
unopsonized THG particles. The results are expressed as the means
SD for 3 separate experiments using cells from 3 different donors.
with A23187 resulted in a mean emission (±sD) of 15.2 5.8 X
iO cpml5 X i0 cells (N = 3).
Effect of alternative glycoprotein target particles
Soluble THG (1 mg/mI), particulate preparations of laminin (2
X i0 particles/mi) and particulate porcine gastric glycoprotein
(2 x io particles/mI) all failed to activate PMN as assessed by
CL, superoxide release and granule protein release. Both these
alternative preparations of particulate glycoproteins in suspen-
sion were of the same size as the particulate THG.
Proteolytic digestion of THG
Fractionation of the pronase digest of particulate THG on
Sephadex G-100 released two major sugar glycopeptide con-
taining fractions which eluted at molecular weights 22000 and
7000 daltons, respectively (Fig. 11). The results of the sugar
analysis of these fractions are shown in Table 1 and demon-
strate that in addition to their difference in molecular size,
fraction II is enriched in mannose, contains reduced glucose
residues and has no detectable amounts of glucosamine. When
incubated with PMN neither fraction activated the respiratory
Trypsin concentration, jsg/mI
Fig. 10. Dose effect of trypsin preincubation on the capacity of 5 x io
PMN to generate luminol dependent CL in response to unopsonized
THG particles. The results are expressed as the means SD for 3
separate experiments using cells from 3 different donors.
Fraction No.
Fig. 11. Gel chromatography of glycopeptides release from THG fol-
lowing digestion with pronase for 24 hours at 37°C. The digestion
products were applied to a Sephadex G- 100 column equilibrated in 0.1
M acetic acid. Fractions I and II were collected and assayed for neutral
sugars.
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burst (data not shown). Furthermore, when incubated over a
wide range of concentrations (0.5 to 4 mg/mI) with particulate
THG (1 mg/mI), they did not inhibit PMN cell activation as
measured by CL.
Discussion
The capacity of particulate THG to activate human PMN
represents a hitherto uncharacterized response. Triggering of
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Table 1. Carbohydrate content of glycopeptides isolated by pronase-
digest of THG
Percent component of total
Fraction I Fraction II
Fucose 5.5 4.3
Mannose 12.0 25.0
Galactose 33.0 36.0
Glucose 27.0 16.0
Glucosamine 5.6 —
Sialic acid 17.0 19.0
the respiratory burst of neutrophils and the release of granule
marker enzymes occur in response to a variety of ligands
including zymosan, aggregated IgG and opsonized glomerular
basement membrane [41—43]. The activation of phagocytic cells
by particulate ligands has been characterized in terms of
respiratory burst activation [44], the release of intracellular
enzymes [41, 45], and the generation of pro-inflammatory
mediators [46]. The results of the present study demonstrates
that this phenomenon occurs when PMN are exposed to par-
ticulate THG. There is considerable evidence that reactive
oxygen metabolites and proteases can contribute directly to
tissue damage [41, 47, 48].
Human PMN avidly ingest particulate THG in a dose and
time-dependent manner with the accompanying generation of
reactive oxygen species, the release of intracellular enzymes
and the oxidative metabolism of arachidonic acid via the 5
lipoxygenase pathway to LTB4. It is unlikely that locally-
synthesized complement components play a role in this inter-
action, since the capacity of PMN to synthesize all the required
alternative complement pathway proteins has yet to be estab-
lished. The ability for particulate THG, however, to activate the
alternative complement pathway is indeed novel and may
represent a mechanism whereby the proposed inflammatory
response is enhanced in vivo. The opsonization of THG in the
present study results in a two- to five-fold increase in cell
activation. The chelation of the divalent cation Ca2 in the
presence of Mg EGTA lead to a 50% decrease in PMN CL
response and highlights the importance of the alternative com-
plement pathway in augmenting the inflammatory response.
The purity of the preparations of THG used is essential for the
validity of the interactions discussed in this study. The prepa-
rations have been rigorously analyzed by SDS/PAGE as well as
direct autoradiography with 1251-Iabelled THG and Western
blotting. A single band of molecular weight 90-95 kD has been
consistently demonstrated with all preparations. This value is in
agreement with published data [5]. That the capacity of PMN to
respond to THG was sensitive to low concentrations of trypsin,
indicates that the major recognition mechanism for the particles
on PMN is a membrane protein. In contrast the preincubation
of cells with trypsin did not influence their response to calcium
ionophore A23 187, a feature which is consistent with our
published observations [28, 49]. In addition, the observation
that the inhibition of phagocytosis by cytochalasin B does not
significantly decrease degranulation indicates that phagocytosis
is not essential for PMN activation by these particles, but that
ligand/cell interaction is sufficient to trigger a cell response.
Such an interaction, although novel, should be considered in
the context of previous studies which suggest an immuno-
regulatory role for THG. The interaction of this glycoprotein
with human lymphocytes has been previously detailed in a
number of studies. In particular, Hunt and McGiven [50]
demonstrated that normal human lymphocytes underwent blast
transformation in the presence of THG to a degree comparable
to that induced by phytohemaglutinin, concanavalin A and
pokeweed mitogen. In contrast, in separate studies, Serafini-
Cessi, Francesci and Sperti [51] and Abbodanza et al [52]
claimed that THG competed with, and reduced, lectin interac-
tion with lymphocytes and inhibited mitogenesis. Further stud-
ies by Hunt et a! [53] also demonstrated that THG was capable
of activating murine macrophages in a chemotactic assay,
although no evidence of direct cell activation was presented.
Clinical correlations have also been suggested where the sensi-
tization of lymphocytes to THG has been demonstrated in
patients with renal tubular acidosis associated with auto-im-
mune liver disease [54]. Such patients exhibited peripheral
lymphocyte sensitization to human THG in a leukocyte migra-
tion test. Whether in fact, THG under these conditions acts as
a non-specific lectin or has a separate recognition mechanism
on the surface of lymphocytes remains to be defined, although
sensitization of certain individuals to the glycoprotein would
suggest that it may behave in a manner analogous to other recall
antigens. More recently, a series of detailed studies involving
uromodulin (THG isolated from the urine of pregnant women)
have demonstrated an interaction between this compound and a
variety of cytokines [55—58]. It has been postulated that there is
a binding site on interleukin- 1 a as well as on recombinant tumor
necrosis factor (TNF) for uromodulin, and that uromodulin may
serve as a mechanism for the clearance via the kidney of these
cytokines. The site of interaction between TNF and uromodulin
appears to reside in the carbohydrate portion of the molecule,
since pronase digestion will produce oligosaccharides that will
inhibit the binding of uromodulin to TNF [59, 60]. In the present
study, the effect of pronase digestion was to totally abolish the
capacity of particulate THG for PMN activation, indicating that
the mechanism of interaction with the cell surface is dependent
on an intact molecule. In addition, the glycopeptides prepared
by pronase digestion were incapable of inhibiting THG activa-
tion of the cell. Thus, the mechanism of interaction with the cell
surface must be distinct from the lectin-like binding of the
glycoprotein to cytokines.
The present study would suggest a potential pathologic
function for THG in its insoluble form to act as a focus for
inflammation within the renal interstitium. It has been previ-
ously suggested that although a significant pathogenic role for
THG may relate to tubular obstruction by urinary casts [61] or
to an increased precipitability of calcium oxalate in urine [62],
the loss of tubular integrity and the resultant extravasation of
urine into the renal interstitium may lead to the triggering of an
inflammatory response. The presence of extra-tubular THG
deposition as insoluble aggregates has been documented in a
number of studies. Such deposits have been detected in med-
ullary cyst disease, obstructive uropathy with VUR, chronic
pyelonephritis and in other forms of tubular interstitial nephritis
[15—17]. In a number of instances these deposits are accompa-
nied by an accumulation of inflammatory cells. Furthermore,
the intra-renal injection of THG in a rat model resulted in a
marked and significant inflammatory cell reaction and subse-
quent scar formation [19]. Thus a role for THG in the patho-
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genesis of interstitial nephritis must be considered. The results
of the present study would indicate that human polymorphonu-
clear leukocytes have on their surface a recognition mechanism
for THG and the interaction between particulate THG and
PMN results in a significant inflammatory response in vitro.
Should such a mechanism prevail in vivo, augmented by the
deposition of complement components on the surface of the
insoluble aggregates, then an exacerbation of the inflammatory
response might well occur within the interstitium of the kidney.
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